Antibody-drug combination outperforms standard treatment of advanced triple-negative breast cancer
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
Year: 2025
Pressing Questions About Your Penis…No Embarrassment Here
LET’S START WITH the obvious: No two penises are exactly alike. Some are bigger, some thinner, and some are more...
New guideline addressed visual impairment after stroke
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
Clinical trial reveals potential new treatment for aggressive form of acute myeloid leukemia
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
Switch to experimental drug after liquid biopsy detection of breast cancer recurrence improves outcomes
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
Excessive daytime sleepiness is associated with mortality in middle-aged women
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
Novel Algorithm Boosts Stroke Triage, Outcomes Across the US
HELSINKI — Use of a novel algorithm significantly improved prehospital triage for stroke, more accurately directing appropriate patients to centers...
EoE Prevalence in US Reaches 1 in 700, Costs $1B Annually
The prevalence of eosinophilic esophagitis (EoE) has increased fivefold in the United States since 2srcsrc9, now affecting about 1 in...
APA Unveils Early Plans for the Next DSM
LOS ANGELES — Exploratory plans for a new iteration of the Diagnostic and Statistical Manual of Mental Disorders (DSM) were...
Cefazolin in Joint Surgery Safe Despite Antibiotic Allergy
TOPLINE:For patients with beta-lactam allergy undergoing orthopedic surgery, prioritizing cefazolin as the preferred antibiotic for the prevention of surgical site...
AI Algorithm Predicts Transfusion Need in Acute GI Bleeds
SAN DIEGO — A novel generative artificial intelligence (AI) framework known as trajectory flow matching (TFM) can predict the need...
ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
You don't have permission to access "http://www.medpagetoday.com/meetingcoverage/asco/115844" on this server. Reference #18.b6e5c417.1748872516.add48e73 https://errors.edgesuite.net/18.b6e5c417.1748872516.add48e73 Read More
NICE recommends mirikizumab for Crohn’s disease treatment
New guidance expands treatment options for eligible patients The National Institute for Health and Care Excellence (NICE) has issued final...
AstraZeneca’s Forxiga recommended for chronic kidney disease treatment
Updated guidance from NICE expands eligibility for dapagliflozin us The National Institute for Health and Care Excellence (NICE) has published...
RFK Jr. Says Healthy Pregnant Women Don’t Need Covid Boosters. What the Science Says.
You’re pregnant, healthy, and hearing mixed messages: Health and Human Services Secretary Robert F. Kennedy Jr., who is not a...
Role Reversal: Millions of Kids Are Caregivers for Elders. Why Their Numbers Might Grow.
ST. PAUL, Minn. — High school senior Joshua Yang understands sacrifice. When he was midway through 1srcth grade, his mom...
Eisai to Launch “Pariet S,” the First Proton Pump Inhibitor RX-to-OTC in Japan
TOKYO, June 2, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of “Pariet®S” (pharmaceutical requiring guidance),...
Application of machine learning in drug side effect prediction: databases, methods and challenges
Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients' physical and...
Double cheer continues for India Inc in Q4 profit growth
Corporate India's net profit surged in the March quarter, driven by reduced non-operating costs, while revenue growth remained moderate. Excluding...
Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL
You don't have permission to access "http://www.medpagetoday.com/meetingcoverage/asco/115842" on this server. Reference #18.ade5c417.1748872522.195src9srcsrc5 https://errors.edgesuite.net/18.ade5c417.1748872522.195src9srcsrc5 Read More
